iSBTc 19th Annual Meeting

November 5-7, 2004
Fairmont Hotel
San Francisco, CA

  • Register for Programs
  • Make Hotel Reservation
  • See Schedule
  • Download Poster Guidelines (PDF)

This state-of-the-art conference will feature keynote addresses, plenary and concurrent sessions and poster presentations. The Society’s distinguished faculty will lead sessions on cutting edge research germane to the field. In addition to the scheduled scientific sessions, the 2004 meeting will include a members/ sponsors-only reception on Friday evening and a Saturday evening Presidential Reception where the winner of the iSBTc Presidential Award will be announced, as well as daily exhibit and poster sessions. These activities will provide meeting attendees with the opportunity to network with colleagues in cancer research. Further information regarding the Annual Meeting is available in the iSBTc 2004 Preliminary Program.

Meeting and Poster Topics

  • Adoptive Immunotherapy
  • Immune Adjuvants
  • Cancer Biometrics
  • Dendritic Cells and Vaccines
  • Mechanisms of Escape/Resistance
  • Cytokines
  • New Agents in Development

Poster Only Topics

  • Hematologic Malignancies
  • Cytokine Based Immunotherapy
  • Antibody Therapy
  • Angiogenesis
  • Imaging
  • Cytokines-Polymorphisms
  • Inhibiting of Inflammatory Mediators
  • Natural Killer Cells & Innate Immunity

Confirmed Faculty

Keynote Speakers:

Carl R. Alving, MD
Walter Reed Army Institute of Research
Silver Spring, MD

Ethan Shevach, MD
National Institutes of Health
Bethesda, MD

Scientific Programming Committee:

James J. Mulé, PhD
H. Lee Moffitt Cancer Center and Research Institute
Tampa, FL

Gary R. Jones, MD
Berlex Laboratories
Seattle, WA

Steven J. O’Day, MD
John Wayne Cancer Institute
Santa Monica, CA

Confirmed Co-Chairs:

George Coukos, MD, PhD – University of Pennsylvania
Steven Hirschfeld, MD, PhD – CBER/FDA
Steve Dubinett, MD – University of California Los Angeles
Bernard Fox, PhD – Earle A. Chiles Research Institute
Tom Gajewski, MD, PhD – University of Chicago Medical Schl.
Eli Gilboa, PhD – Duke University Medical Center
Jared Gollob, MD – Duke University Medical Center
Patrick Hwu, MD – MD Anderson Cancer Center
Gary Jones, MD – Berlex Laboratories
Michael Lotze, MD – University of Pittsburgh
Don Morton, MD – John Wayne Cancer Institute
David Munn, MD – Medical College Georgia
Steven O’Day, MD – John Wayne Cancer Institute
Craig Slingluff, MD – University of Virginia
Jeff Weber, MD, PhD – Norris Cancer Center

Confirmed Speakers:

Michael B. Atkins, MD – Beth Israel Deaconess Medical Ctr.
Steven Dubinett, MD – University of California Los Angeles
Bernard A. Fox, PhD – Earle A. Chiles Research Institute
Yang-Xin Fu, MD, PhD – University of Chicago
Thomas Gajewski, MD, PhD – Univ. of Chicago Medical Schl.
Eli Gilboa, PhD – Duke University Medical School
Jared A. Gollob, MD – Duke University Medical Center
Steven Hirschfeld, MD, PhD – FDA
Patrick Hwu, MD – MD Anderson Cancer Center
Peter Jones, PhD – USC/Norris Comprehensive Cancer Ctr.
Larry Kwak, MD PhD – MD Anderson Cancer Center
Philip O. Livingston, MD – Mem. Sloan-Kettering Cancer Ctr.
Donald L. Morton, MD – John Wayne Cancer Institute
David Munn, MD – Medical College Georgia
Emanuel Petricoin, MD – CBER/FDA
Dirk Shadendorf, MD – German Cancer Research Center
Yu Shyr, MD – Vanderbilt University School of Medicine
Johannes Vieweg, MD – Duke University Medical Center
Pallavur V. Sivakumar, PhD – Zymogenetics Inc.